Dr. Junhua Tao, originator and Chief Scientist of BioVerdant Bio-Tech Co., USA, was invited to visit DICP by Prof. LI Can, Vice-Director of DICP and Member of CAS, on 4th August. Dr. Tao was also the originator and department head of the Bio-Conversion Research Center of Pfizer, Inc. USA. He is engaging in the R&D of biocatalysts and their applications in pharmaceutical and chemical developments.
During his visit, Dr. Tao was invited to give a lecture titled "Recent Advances of Biocatalysis in Pharmaceutical Development". He described in his lecture how to synthesize new drugs such as Pregabalin, Atorvastatin Calcium, and Levetiracetam£¬Keppra via biocatalysis and techniques based on cloning, bio-informatics, genomics, proteomics, protein evolution and high through-put screening. The lecture session was chaired by Prof. ZOU Hanfa of DICP.
Dr. Tao was also invited to tour the Bio-Tech Division and the State Key Lab of Catalysis of DICP. He conducted in-depth discussions with DICP scientists during his stay in the institute.